Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 20, Issue 2, Pages 259-267
Publisher
Oxford University Press (OUP)
Online
2017-08-16
DOI
10.1093/neuonc/nox151
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
- (2017) David A. Reardon et al. Journal of the National Comprehensive Cancer Network
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
- (2014) R. Rahman et al. NEURO-ONCOLOGY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
- (2013) A. Jahangiri et al. CLINICAL CANCER RESEARCH
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2
- (2013) Anna C. Navis et al. PLoS One
- Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
- (2012) D A Reardon et al. BRITISH JOURNAL OF CANCER
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Continuous daily sunitinib for recurrent glioblastoma
- (2012) Teri Nguyen Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
- (2011) W.-K. You et al. CANCER RESEARCH
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
- (2011) P. Y. Wen et al. NEURO-ONCOLOGY
- Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
- (2011) W. B. Pope et al. NEUROLOGY
- c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme
- (2010) Wei Liu et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
- (2010) C. Lu-Emerson et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma
- (2010) B. Neyns et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
- (2010) B. J. Scott et al. NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
- (2009) Eudocia C. Quant et al. NEURO-ONCOLOGY
- Prognostic significance of c-Met expression in glioblastomas
- (2008) Doo-Sik Kong et al. CANCER
- Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
- (2008) M. Hutterer et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started